Related Experiment Video
Updated: Apr 15, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
Increased LDL electronegativity in chronic kidney disease disrupts calcium homeostasis resulting in cardiac
Kuan-Cheng Chang1, An-Sheng Lee2, Wei-Yu Chen3
1Division of Cardiology, China Medical University (CMU) Hospital, Taichung, Taiwan; Graduate Institute of Clinical Medical Science, CMU, Taichung, Taiwan.
Insights
Electronegative low-density lipoprotein (LDL) is linked to cardiac dysfunction in early chronic kidney disease (CKD). This altered LDL disrupts calcium handling in heart cells, potentially explaining cardiorenal syndrome.
Area of Science:
- Cardiology
- Nephrology
- Biochemistry
Background:
- Chronic kidney disease (CKD) is a significant risk factor for cardiovascular disease, often involving abnormal lipoprotein metabolism.
- Early-stage CKD is associated with cardiac dysfunction, but the underlying mechanisms remain unclear.
Purpose of the Study:
- To investigate the mechanistic link between electronegative low-density lipoprotein (LDL) and cardiac dysfunction in early CKD.
- To explore the role of LDL electronegativity in impaired cardiac relaxation and calcium homeostasis.
Main Methods:
- Compared echocardiographic parameters in stage 2 CKD patients and controls.
- Analyzed cardiac function using pressure-volume loop data in a rat model of CKD (unilateral nephrectomy).
- Investigated LDL electronegativity, its effects on H9c2 cardiomyocytes, and its signaling via LOX-1 in wild-type and LOX-1 knockout mice.
Main Results:
- Impaired cardiac relaxation was more prevalent in CKD patients and UNx rats.
- Reduced estimated glomerular filtration rate independently predicted left ventricular relaxation dysfunction.
- Electronegative LDL from CKD patients and UNx rats induced intracellular calcium overload and cardiac relaxation dysfunction, mediated by LOX-1 and nitric oxide pathways.
Conclusions:
- LDL becomes more electronegative in early CKD, contributing to cardiac dysfunction.
- This electronegative LDL disrupts SERCA2a-regulated calcium homeostasis, a potential mechanism for cardiorenal syndrome.
- Targeting electronegative LDL or its signaling pathways may offer therapeutic strategies for cardiorenal complications.
Abstract:
Chronic kidney disease (CKD), an independent risk factor for cardiovascular disease, is associated with abnormal lipoprotein metabolism. We examined whether electronegative low-density lipoprotein (LDL) is mechanistically linked to cardiac dysfunction in patients with early CKD. We compared echocardiographic parameters between patients with stage 2 CKD (n = 88) and normal controls (n = 89) and found that impaired relaxation was more common in CKD patients. Reduction in estimated glomerular filtration rate was an independent predictor of left ventricular relaxation dysfunction. We then examined cardiac function in a rat model of early CKD induced by unilateral nephrectomy (UNx) by analyzing pressure-volume loop data. The time constant of isovolumic pressure decay was longer and the maximal velocity of pressure fall was slower in UNx rats than in controls. When we investigated the mechanisms underlying relaxation dysfunction, we found that LDL from CKD patients and UNx rats was more electronegative than LDL from their respective controls and that LDL from UNx rats induced intracellular calcium overload in H9c2 cardiomyocytes in vitro. Furthermore, chronic administration of electronegative LDL, which signals through lectin-like oxidized LDL receptor-1 (LOX-1), induced relaxation dysfunction in wild-type but not LOX-1(-/-) mice. In in vitro and in vivo experiments, impaired cardiac relaxation was associated with increased calcium transient resulting from nitric oxide (NO)-dependent nitrosylation of SERCA2a due to increases in inducible NO synthase expression and endothelial NO synthase uncoupling. In conclusion, LDL becomes more electronegative in early CKD. This change disrupts SERCA2a-regulated calcium homeostasis, which may be the mechanism underlying cardiorenal syndrome.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease IV: Nursing Management
Chronic Kidney Disease III: Interprofessional Care
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology

